CAMP4 Therapeutics Q1 profit misses estimates, net loss widens

CAMP4 Therapeutics

07/05/2026 22:15

Overview

US biopharmaceutical company's Q1 adjusted EPS missed analyst expectations

Net loss widened yr/yr due to non-cash loss from derivative tranche liability

Company submitted first clinical trial regulatory filing for CMP-002 in Australia

Outlook

Company anticipates global Phase 1/2 clinical trial for CMP-002 to begin in 2H 2026

CAMP4 expects additional global regulatory filings for CMP-002 throughout 2026

Company expects cash runway to fund planned activities into 2028

Result Drivers

DERIVATIVE LIABILITY - Net loss increased due to a $6.2 mln non-cash loss from change in fair value of derivative tranche liability related to September private placement

R&D SPENDING - Research and development expenses were mainly driven by clinical and preclinical study costs

G&A COSTS - Higher general and administrative expenses reflected increased stock-based compensation and professional fees, partly offset by lower facilities costs

Company press release: ID:nGNX5kDb53

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
Miss
-$0.32
-$0.21 (5 Analysts)
Q1 Income From Operations
-$13.07 mln
Q1 Operating Expenses
$14.37 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for CAMP4 Therapeutics Corp is $8.50, about 109.4% above its May 6 closing price of $4.06

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)